Diagnostics

Danielle Cimmento-Burkey’s appointment as Director of Strategy & Leadership signals a new phase of disciplined expansion for the fast-growing diagnostics firm.

As MedTech pioneers quantum sensing and AI, it faces a regulatory maze and a mandate for inclusivity. MEDevice Boston 2026 charts the path forward.

A simple urine test could soon detect cancer early. With $33M in fresh funding, Japanese bio-AI firm Craif is betting its tech can change U.S. healthcare.

A Utah diagnostics firm is at the FDA's door with a point-of-care PCR system. It’s a bid to redefine testing, but giants and regulatory hurdles loom large.

An AI tool just received FDA clearance to quantify Alzheimer's biomarkers in brain scans. It promises earlier answers, but raises profound questions for patients and our healthcare system.

As the at-home diagnostics market heats up, Aptitude Medical Systems doubles down on its leadership, appointing a co-CEO to accelerate its commercial future.

20/20 BioLabs' record revenue is just the surface. Underneath, the company is building an AI-powered health network, starting with firefighters and cities.

Shedding its IT baggage, Vaso Corp's Q2 results reveal a focused, profitable healthcare strategy. Is this the new blueprint for MedTech success?

Lucid Diagnostics reports rising revenue and a key insurance win for its EsoGuard test, but its financial future hangs in the balance of a pivotal Medicare decision.

HMI Medical's major acquisition of Lifescan Imaging isn't just about market share; it's a strategic move to build a blueprint for Singapore's future.

Amprion's expansion of its alpha-synuclein test to Europe isn't just a deal; it's the build-out of a new infrastructure for understanding the brain.

As BioPorto preps its H1 2026 results, its promising NGAL kidney test faces a crucial moment. Can it sustain growth and appease a global market?

With FDA clearance for its AI burn scanner, Spectral AI faces its next test: conquering the market. Can it turn government contracts into commercial success?

As VolitionRx readies its Q2 update, investors and scientists look for proof that its pioneering epigenetic tests can translate into commercial success.

OTraces' new AI analyzes biological 'noise' to forecast Type 1 Diabetes with over 92% accuracy, promising a new era of early intervention and care.

A new report reveals undiagnosed testosterone deficiency could cost the U.S. up to $525 billion, but the real story is about the millions of men being missed.

A new blood test for Alzheimer's from Spear Bio wins a top tech award. Its unprecedented sensitivity could revolutionize early detection and treatment.

Amid a dire shortage of radiologists and soaring diagnostic wait times, 12 top U.S. health systems are partnering with Aidoc to deploy AI at scale.

Insight Molecular Diagnostics has key regulatory and reimbursement wins for its game-changing transplant test, but a high cash burn creates a high-stakes race to commercialization.

Beyond the record revenue, Applied BioCode's growth reveals a strategy of solving lab bottlenecks and securing reimbursement, positioning it against industry giants.